Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS

Affiliation

• ¹ Institute of Neuroimmunology and Multiple Sclerosis (S.C.H., K.H.S., M.A.F., C.H.), Department of Neurology (S.C.H., K.H.S., C.H.), and Department of Diagnostic and Interventional Neuroradiology (B.H.), University Medical Center Hamburg-Eppendorf; and Neurological Private Practice (V.B., B.E.), Hamburg, Germany.